AUTHOR=Godzien Joanna , Lopez-Lopez Angeles , Sieminska Julia , Jablonowski Kacper , Pietrowska Karolina , Kisluk Joanna , Mojsak Malgorzata , Dzieciol-Anikiej Zofia , Barbas Coral , Reszec Joanna , Kozlowski Miroslaw , Moniuszko Marcin , Kretowski Adam , Niklinski Jacek , Ciborowski Michal 

TITLE=Exploration of oxidized phosphocholine profile in non-small-cell lung cancer

JOURNAL=Frontiers in Molecular Biosciences

VOLUME=10

YEAR=2024

URL=https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1279645

DOI=10.3389/fmolb.2023.1279645

ISSN=2296-889X

ABSTRACT=<p><bold>Introduction:</bold> Lung cancer is one of the most frequently studied types of cancer and represents the most common and lethal neoplasm. Our previous research on non-small cell lung cancer (NSCLC) has revealed deep lipid profile reprogramming and redox status disruption in cancer patients. Lung cell membranes are rich in phospholipids that are susceptible to oxidation, leading to the formation of bioactive oxidized phosphatidylcholines (oxPCs). Persistent and elevated levels of oxPCs have been shown to induce chronic inflammation, leading to detrimental effects. However, recent reports suggest that certain oxPCs possess anti-inflammatory, pro-survival, and endothelial barrier-protective properties. Thus, we aimed to measure the levels of oxPCs in NSCLC patients and investigate their potential role in lung cancer.</p><p><bold>Methods:</bold> To explore the oxPCs profiles in lung cancer, we performed in-depth, multi-level metabolomic analyses of nearly 350 plasma and lung tissue samples from 200 patients with NSCLC, including adenocarcinoma (ADC) and squamous cell carcinoma (SCC), the two most prevalent NSCLC subtypes and COPD patients as a control group. First, we performed oxPC profiling of plasma samples. Second, we analyzed tumor and non-cancerous lung tissues collected during the surgical removal of NSCLC tumors. Because of tumor tissue heterogeneity, subsequent analyses covered the surrounding healthy tissue and peripheral and central tumors. To assess whether the observed phenotypic changes in the patients were associated with measured oxPC levels, metabolomics data were augmented with data from medical records.</p><p><bold>Results:</bold> We observed a predominance of long-chain oxPCs in plasma samples and of short-chain oxPCs in tissue samples from patients with NSCLC. The highest concentration of oxPCs was observed in the central tumor region. ADC patients showed higher levels of oxPCs compared to the control group, than patients with SCC.</p><p><bold>Conclusion:</bold> The detrimental effects associated with the accumulation of short-chain oxPCs suggest that these molecules may have greater therapeutic utility than diagnostic value, especially given that elevated oxPC levels are a hallmark of multiple types of cancer.</p>